Please use this identifier to cite or link to this item: https://hdl.handle.net/10316/113916
Title: Increased ATP Release and Higher Impact of Adenosine A2A Receptors on Corticostriatal Plasticity in a Rat Model of Presymptomatic Parkinson's Disease
Authors: Gonçalves, Francisco Q. 
Matheus, Filipe C.
Silva, Henrique B. 
Real, Joana I. 
Rial, Daniel 
Rodrigues, Ricardo J. 
Oses, Jean-Pierre
Silva, Antonio C. 
Gonçalves, Nélio 
Prediger, Rui D.
Tomé, Ângelo R. 
Cunha, Rodrigo A. 
Keywords: Adenosine; Ecto-5′-nucleotidase; A2A receptors; Parkinson’s disease; ATP
Issue Date: Mar-2023
Publisher: Springer Nature
Project: LCF/PR/HP17/52190001 
CENTRO-01–0145-FEDER-000008 
CENTRO-01–0246-FEDER-000010 
POCI-01–0145- FEDER-03127 
UIDB/04539/2020 
metadata.degois.publication.title: Molecular Neurobiology
metadata.degois.publication.volume: 60
metadata.degois.publication.issue: 3
Abstract: Extracellular ATP can be a danger signal, but its role in striatal circuits afflicted in Parkinson's disease (PD) is unclear and was now investigated. ATP was particularly released at high stimulation intensities from purified striatal nerve terminals of mice, which were endowed with different ATP-P2 receptors (P2R), although P2R antagonists did not alter corticostriatal transmission or plasticity. Instead, ATP was extracellularly catabolized into adenosine through CD73 to activate adenosine A2A receptors (A2AR) modulating corticostriatal long-term potentiation (LTP) in mice. In the presymptomatic phase of a 6-hydroxydopamine rat model of PD, ATP release from striatal nerve terminals was increased and was responsible for a greater impact of CD73 and A2AR on corticostriatal LTP. These observations identify increased ATP release and ATP-derived formation of extracellular adenosine bolstering A2AR activation as a key pathway responsible for abnormal synaptic plasticity in circuits involved in the onset of PD motor symptoms. The translation of these findings to humans prompts extending the use of A2AR antagonists from only co-adjuvants of motor control in Parkinsonian patients to neuroprotective drugs delaying the onset of motor symptoms.
URI: https://hdl.handle.net/10316/113916
ISSN: 0893-7648
1559-1182
DOI: 10.1007/s12035-022-03162-1
Rights: openAccess
Appears in Collections:FCTUC Ciências da Vida - Artigos em Revistas Internacionais
I&D CNC - Artigos em Revistas Internacionais
FMUC Medicina - Artigos em Revistas Internacionais

Show full item record

Page view(s)

75
checked on Nov 5, 2024

Download(s)

22
checked on Nov 5, 2024

Google ScholarTM

Check

Altmetric

Altmetric


This item is licensed under a Creative Commons License Creative Commons